BENEV

Name

BENEV

Legal name

BENEV Company Inc.

Website

https://benev.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Aesthetic Devices and Cosmeceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

akta.pro secondary industries

Dermatology Specialty Pharmaceuticals (HLAIACAL), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Medical aesthetic devices
• Exosome skincare products
• RF microneedling systems
• Physician-dispensed cosmeceuticals
• Regenerative aesthetic products

Headquarters

HQ city

Mission Viejo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. Medical Device Sales: BENEV generates revenue through sale of FDA-cleared medical devices including Sylfirm X RF microneedling system, XTherma skin tightening device, and SmartLux phototherapy device to aesthetic practices and clinics.
2. Skincare & Exosome Products: Sale of proprietary skincare products including Exosome Regenerative Complex, Exosome Regenerative Complex+, EXO Balm, and Viviscal Pro through physician practices. Products distributed exclusively through licensed medical professionals.
3. Aesthetic Injectables: Distribution of Letybo (letibotulinumtoxinA-wlbg) botulinum toxin product through partnership with Hugel Inc. Letybo received FDA approval and is commercialized through BENEV's U.S. market presence.
4. BENEV Lab Contract Manufacturing: BENEV Lab provides complete formulating and manufacturing services for private label lines and contract manufacturers. Offers in-house clinical testing, custom marketing packages, formula bank, medical device solutions, and FDA regulation consulting.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

BENEV manufactures and sells FDA-registered medical devices (Sylfirm X dual wave RF microneedling, XTherma RF/cryogen skin tightening, SmartLux Mini SLD phototherapy) and proprietary exosome-based regenerative skincare products (ERC, ERC+, EXO Balm), as well as Miracu PDO threads, Viviscal PRO hair restoration line, and the FDA-approved botulinum toxin Letybo. All products are developed, formulated, and manufactured at the company's FDA-registered facility in Mission Viejo, California, and distributed exclusively through licensed physicians in the U.S. and through international distributors abroad.

Product overview

BENEV Company Inc. is a U.S. FDA-registered pharmaceutical, cosmeceutical, and medical device company offering a portfolio of regenerative aesthetic products and devices. The product ecosystem centers on three main pillars: (1) Energy-based medical devices including Sylfirm X (dual-wave RF microneedling), SmartLux Mini (phototherapy), and XTherma (RF/cryogen combination); (2) Exosome-based regenerative products including Exosome Regenerative Complex (ERC), ERC+, and EXO Balm for post-treatment recovery; and (3) Complementary aesthetic products including Viviscal PRO (hair restoration), Miracu PDO threads (thread lifts), and Letybo (neuromodulator). Products are distributed exclusively through physicians in the U.S. and through international distributors.

Differentiator

Problem solved

Functional benefit

Products and services

• Sylfirm X The world's first pulsed wave and continuous wave RF microneedling device for skin rejuvenation, treating discoloration, laxity, tone, texture, and scar appearance. FDA-cleared with interchangeable continuous and pulsed waveforms, four unique wavelengths per mode, and treatment depths from 0.3mm (DEJ) to 4.0mm. Sold to licensed medical aesthetic practices.
• Exosome Regenerative Complex (ERC) Clinically proven topical exosome treatment containing stem cell-derived lyophilized exosomes, growth factors, peptides, coenzymes, minerals, amino acids, and vitamins for skin and scalp rejuvenation. Paraben-free, steroid-free, and hypoallergenic. Sold exclusively through licensed physicians.
• Exosome Regenerative Complex+ (ERC+) More potent version of the Exosome Regenerative Complex with dual-action breakthrough technology designed to absorb quickly into skin, delivering concentrated exosomes with irritation reduction agents. Sold through licensed physicians.
• SmartLux Mini Premium SLD (Superluminescent Diode) phototherapy device using low-level light therapy for skin restoration through multiple wavelengths (420nm, 590nm, 635nm, 830nm). Features adjustable wavelength settings, contoured panel design, and fan-based cooling for consistent energy output. Sold to medical aesthetic practices.
• XTherma High-frequency RF and cryogen combination therapy device for non-invasive skin tightening. FDA-cleared for the U.S. market. Sold to medical aesthetic practices.
• EXO Balm Clinically proven home-care post-treatment balm combining lyophilized exosomes with intensive hydrators to optimize treatment results and reduce downtime. Sold through physicians for take-home patient use.
• Viviscal PRO Clinically proven, drug-free hair restoration solution available in shampoo, conditioner, elixir, and dietary supplement forms, backed by over 25 years of research. Sold through physicians for thinning hair and scalp health.
• Miracu PDO Threads Medical-grade, absorbable PDO (polydioxanone) sutures serving as non-surgical facelift alternatives, including Elasty Line, Meshfill, Forte, and Forte Fix variants. Sold to licensed medical practitioners for thread lift procedures.
• Letybo (letibotulinumtoxinA-wlbg) FDA-approved botulinum toxin product for treating glabellar lines, commercialized in the U.S. through the BENEV and Hugel Inc. partnership. Distributed through licensed physicians.
• BENEV Skincare Line Medical-grade skincare line including masks, growth factors, and professional-use products distributed exclusively through physicians for in-clinic and at-home patient use.
• BENEV Lab Contract Manufacturing Services Complete formulating and manufacturing services for private label lines and contract manufacturers, including in-house clinical testing, custom marketing packages, formula bank access, medical device solutions, and FDA regulation consulting. Serves beauty brands and businesses seeking proprietary skincare lines.

Quantifiable outcome

• 300% increase in elastin production with exosome treatment
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Hugel Inc.coreStrategic or Co-development Partner · 25 March 2025BENEV Company, Inc. and Hugel Inc. partnership for U.S. commercialization of Letybo (letibotulinumtoxinA-wlbg), a botulinum toxin product. Letybo became only the 6th neuromodulator to receive FDA approval in over 20 years, with over 31 million successful treatments recorded globally across 65 countries. The collaboration leverages BENEV's U.S. market presence and Hugel's position as the only South Korean company with regulatory approvals in the three largest botulinum toxin markets (U.S., China, and Europe).
• ExoCoBiocoreTechnology or IntegrationExoCoBio is the strategic technology partner providing exosome manufacturing capabilities. ExoCoBio CEO and CTO Byong Cho led development of Exo-SCRT technology. In 2017, ExoCoBio became the first company to register an exosome with the International Nomenclature Cosmetic Ingredient (INCI) name in the Personal Care Product Council (PCPC). ExoCoBio maintains the highest number of exosome registrations in the ICID and developed patented Exo-SCRT technology for mass manufacturing at consistent quality in GMP compliance.
• RealSelfminorGTM or Marketing PartnerRealSelf partnership helps providers showcase patient results, market services, gather reviews, and generate patient leads. BENEV promotes RealSelf integration to help physicians drive more patients into their practices using BENEV products.
• Mei Vu (Clinical Study)minorStrategic or Co-development PartnerPatient trial photos and clinical study conducted using Mei Vu methodology to validate BENEV Exosome Regenerative Complex efficacy. Study participants experienced no irritation and reported noticeable immediate difference in skin appearance after first treatment with full results after 3rd-5th treatment.

Scale indicators8 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Cutera: Cutera develops and commercializes energy-based aesthetic devices (laser, RF) sold through dermatologists and plastic surgeons. Comparable in product category, physician-channel distribution, and target customer base to BENEV.
• Cynosure (Hologic): Cynosure manufactures energy-based aesthetic devices (RF microneedling, laser, body contouring) sold to medical aesthetic practices. Directly comparable to BENEV's Sylfirm X and energy-based device portfolio.
• Evolus: Evolus commercializes Jeuveau, a neuromodulator competing in the same physician-channel aesthetic injectable space as BENEV's Letybo. Comparable business model focused on aesthetic practices with neuromodulator products.
• ExoCoBio: ExoCoBio is BENEV's strategic technology partner and direct exosome competitor, having developed the Exo-SCRT manufacturing platform that powers BENEV's exosome products. Both companies operate in the cosmetic exosome category with INCI-registered ingredients.
• InMode: InMode is a direct competitor in RF-based aesthetic devices (Morpheus8 RF microneedling, BodyTite, FaceTite). Its Morpheus8 product competes head-to-head with BENEV's Sylfirm X in the RF microneedling category for physician practices.
• Solta Medical: Solta Medical (a Bausch Health company) is a direct competitor in energy-based aesthetic devices, particularly with Thermage RF skin tightening — the same category BENEV's XTherma enters. Both companies sell FDA-cleared aesthetic devices through physician channels in the U.S.

Broad incumbents

• SkinCeuticals (L'Oréal): SkinCeuticals is a medical-grade skincare brand owned by L'Oréal, sold through physicians and medical spas. Comparable to BENEV's professional skincare line in distribution channel and target customer (physician-dispensed skincare).
• Merz Aesthetics: Merz Aesthetics is a major incumbent in aesthetic injectables (Xeomin, Belotero, Radiesse) and skincare (Neocutis). Comparable in physician-channel aesthetic distribution and product breadth to BENEV.
• Allergan Aesthetics (AbbVie): AbbVie's Allergan Aesthetics division is the dominant player in the neuromodulator market with Botox and competes broadly across the aesthetic space (fillers, devices, skincare). BENEV's Letybo partnership directly challenges Botox in the same physician-channel category.
• Galderma: Galderma is a major dermatology-focused aesthetics company with neuromodulators (Dysport), fillers, and skincare lines sold through physicians. Comparable to BENEV in its physician-only distribution model and dermatology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@BENEVofficial
• Facebookfacebook.com/BENEVSkinScience
• LinkedInlinkedin.com/company/benev-company-inc
• Instagraminstagram.com/benevskinscience/?hl=en
• Xx.com/benevskincare

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BENEV